Advertisement
J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1194/jlr.M800303-JLR200 on July 15, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M800303-JLR200v1
49/11/2452    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Svenson, K. L.
Right arrow Articles by Peters, L. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Svenson, K. L.
Right arrow Articles by Peters, L. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 49, 2452-2462, November 2008
Copyright © 2008 by American Society for Biochemistry and Molecular Biology

A new mouse mutant for the LDL receptor identified using ENU mutagenesis*

Karen L. Svenson2,*, Nadav Ahituv1,{dagger}, Rebecca S. Durgin*, Holly Savage*, Phyllis A. Magnani*, Oded Foreman*, Beverly Paigen* and Luanne L. Peters*

* The Jackson Laboratory, Bar Harbor, ME 04609
{dagger} Genomics Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720
1 Present address: Department of Biopharmaceutical Sciences and Institute for Human Genetics, University of California San Fransisco, San Francisco, CA 94143.

* This work was supported by National Heart, Lung, and Blood Institute programs for genomic applications, Grant HL-66611.

Published, JLR Papers in Press, July 15, 2008.

2 To whom correspondence should be addressed. e-mail: ksven{at}jax.org

In an effort to discover new mouse models of cardiovascular disease using N-ethyl-N-nitrosourea (ENU) mutagenesis followed by high-throughput phenotyping, we have identified a new mouse mutation, C699Y, in the LDL receptor (Ldlr), named wicked high cholesterol (WHC). When WHC was compared with the widely used Ldlr knockout (KO) mouse, notable phenotypic differences between strains were observed, such as accelerated atherosclerotic lesion formation and reduced hepatosteatosis in the ENU mutant after a short exposure to an atherogenic diet. This loss-of-function mouse model carries a single base mutation in the Ldlr gene on an otherwise pure C57BL/6J (B6) genetic background, making it a useful new tool for understanding the pathophysiology of atherosclerosis and for evaluating additional genetic modifiers regulating hyperlipidemia and atherogenesis. Further investigation of genomic differences between the ENU mutant and KO strains may reveal previously unappreciated sequence functionality.

Supplementary key words N-ethyl-N-nitrosourea • atherosclerosis • hyperlipidemia • high-throughput phenotyping

Abbreviations: Apoe, apolipoprotein E; ATH, atherogenic; ENU, N-ethyl-N-nitrosourea; FH, familial hypercholesterolemia; G3, three-generation; KO, knockout; Ldlr, LDL receptor; WHC, wicked high cholesterol


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement